EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Post-marketing safety profile of meningococcal group B vaccines: a real-world disproportionality analysis of the VAERS database, 2015Q1–2025Q3

Guojun Liang, Hao Huang, Jihui Huang, Qiong Liu, Yang Song

Frontiers in Pharmacology · 18.03.2026 · 17

DOI: 10.3389/fphar.2026.1745876 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.03.2026. Verfasst von Guojun Liang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Huadu District People's Hospital of Guangzhou, Guangzhou, Guangdong, China. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Serogroup B meningococcal (MenB) disease remains a serious public health concern. Recombinant protein-based vaccines have been licensed since the mid-2010s, but ongoing surveillance is needed to capture rare or long-term adverse events.

Methods

We analyzed reports submitted to the Vaccine Adverse Event Reporting System (VAERS) from 2015Q1 to 2025Q3,with data available through 30 September 2025. Cases explicitly identifying MenB vaccines were included. Events were coded with MedDRA, and disproportionality analyses were conducted using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Empirical Bayes Geometric Mean (EBGM). Subgroup analyses assessed differences by age, sex, seriousness, and coadministration.

Results

A total of 16,611 reports were identified, of which 19.9% were serious. Most events reflected expected reactogenicity such as fever, syncope, headache, and injection site reactions. Several unlabeled events, including pallor and hypotonia, showed elevated RORs. Time-to-onset analyses demonstrated clustering within 2 days of vaccination across all strata, with serious events occurring earlier than non-serious events. No novel syndromic clusters were observed.

Conclusion

MenB vaccines show a favorable safety profile in real-world use. While most events align with established product information, a small number of disproportionate but unlabeled events merit continued pharmacovigilance.

Schlagwörter

Stichwörter der Autor:innen

Neisseria meningitidis serogroup BVAERSmeningococcal vaccinespharmacovigilancevaccine safety

Autor:innen und Institutionen

  • Huadu District People's Hospital of Guangzhou, Guangzhou, Guangdong, China.

Zitieren

APA

Liang, G., Huang, H., Huang, J., Liu, Q., & Song, Y. (2026). Post-marketing safety profile of meningococcal group B vaccines: a real-world disproportionality analysis of the VAERS database, 2015Q1–2025Q3. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1745876

Vancouver

Liang G, Huang H, Huang J, Liu Q, Song Y. Post-marketing safety profile of meningococcal group B vaccines: a real-world disproportionality analysis of the VAERS database, 2015Q1–2025Q3. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1745876

BibTeX
@article{Liang2026,
  author = {Liang, Guojun and Huang, Hao and Huang, Jihui and Liu, Qiong and Song, Yang},
  title = {Post-marketing safety profile of meningococcal group B vaccines: a real-world disproportionality analysis of the VAERS database, 2015Q1–2025Q3},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1745876}
}
Kostenlos starten →